Form 4: Ultragenyx Executive Receives Equity Compensation

EVP and Chief Legal Officer Karah Parschauer was granted restricted stock units and stock options as part of the company's 2023 Incentive Plan.

Summary

• Karah Parschauer, EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., received an equity grant on April 16, 2026.
• The grant includes 28,895 Restricted Stock Units (RSUs) which vest over four years.
• The grant also includes 49,960 stock options with an exercise price of $24.52 per share.
• Following these transactions, the reporting person holds 95,715 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company strategy or financial health.

Positives

• Equity-based compensation aligns executive interests with long-term shareholder value creation.
• The vesting schedule for both RSUs and options encourages executive retention over a multi-year period.

Negatives

• The issuance of new equity awards results in potential dilution for existing shareholders.

Risks

• Future share price volatility may impact the ultimate value realized by the executive from these equity grants.
• Vesting is subject to continued employment, which carries inherent human capital risk.

Future Outlook

The equity grants are subject to standard vesting schedules: RSUs vest 1/4th annually over four years, while options vest 1/4th on the first anniversary followed by monthly vesting over the subsequent three years.

Management Comments

• The transactions were executed under the Company's 2023 Incentive Plan.

Industry Context

StockSavvy.ai notes that equity-based compensation remains the standard mechanism for incentivizing C-suite executives in the biotechnology sector to focus on long-term clinical and commercial milestones.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.
• The use of both RSUs and stock options is a common hybrid approach to balance retention and performance-based incentives.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of these equity awards.

Next Steps

• Vesting of 1/4th of the RSU grant on April 16, 2027.
• Vesting of 1/4th of the stock option grant on April 16, 2027.

Key Dates

Keywords

Ultragenyx, RARE, Form 4, Insider Trading, Equity Compensation, Executive Compensation